Blocking PD-1 and PD-L1 can restore the function of effector CD8+ T cells [27], while anti-CTLA-4 therapy can increase the abundance of CD4+ T and CD8+ T cells in HCC patients [28, 29]. Here, CTLA4 is linked to hepatocellular carcinoma.